Worried about your memory?

Johns Hopkins is conducting a Phase 3 Clinical to determine whether an investigational drug known as AGB101 will slow progression of mild cognitive impairment (MCI), a condition that increases risk for Alzheimer’s Disease.

You may be eligible for this research study if you:

- Have memory changes or mild cognitive impairment (MCI)
- Are between 55-85 years old

Participation includes:

- Up to 10 visits over 18 months
- Tests of memory, thinking, and behavior
- PET and MRI scans of your brain
- Giving blood and urine samples
- Taking either AGB101 or placebo
- Compensation of up to $700

For more information, contact:
410-502-4797
HOPE4MCI@jhu.edu

Principal Investigator: Marilyn Albert, Ph.D.
Protocol #: IRB00101152